<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044083</url>
  </required_header>
  <id_info>
    <org_study_id>020239</org_study_id>
    <secondary_id>02-M-0239</secondary_id>
    <nct_id>NCT00044083</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Tolcapone for Cognition in Schizophrenia</brief_title>
  <official_title>Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Tolcapone and Entacapone on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well
      as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention
      Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the
      frontal cortex of the brain.

      ...
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psychopharmacological modulation of the catecholaminergic system can enhance some aspects of
      cognitive function. For example, COMT inhibitors can slightly improve working
      memory/executive function. Differences in the response between individuals might be related
      to a number of factors, including variations in the genes. The recent finding that a
      polymorphism in the catechol-o-methyl-transferase (COMT) gene, which produces a 4 fold change
      in enzyme activity, accounts for 4 percent of the variance in performance of working memory
      tasks in humans suggest that COMT genotype may predict response to COMT inhibitors. In the
      present investigation our goal is to examine, in normal controls and patients with
      schizophrenia, the effect of a centrally acting (tolcapone) and of a peripherally acting
      (entacapone) COMT inhibitor on cognitive function. We predict that both normal controls and
      patients with schizophrenia with the val/val genotype will have a significant, though
      transient, improvement in working memory in subjects treated with tolcapone but not in those
      treated with entacapone. Furthermore, in conjunction with other NIMH imaging protocols, we
      would like to examine the neurophysiological correlates related to working memory. We
      predict, in tolcapone treated subjects, improved measures in prefrontal 'efficiency' in
      subjects and patients specifically with the val/val genotype. The present protocol will
      provide new insights on the importance of this genetic polymorphism in the regulation of
      aminergic-controlled cognitive function in normal individuals. Furthermore, this protocol
      will test whether COMT inhibitors offer a new treatment-based on genotype - for cognitive
      impairment in schizophrenia. No IND is required for the present study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Scientific Director request to use resources for other studies
  </why_stopped>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>N-Back Task Performance</measure>
    <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
    <description>Working Memory was measured in HVs and patients with schizophrenia after a 7-day treatment with Tolcapone or placebo in a double-blind, cross-over fashion. The working memory was quantified by taking the number of trials entered correctly divided by the total number of trials multiplied by 100. Values range from 0 to 100. Zero indicates the poorest performance while 100 indicates perfect performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>N-Back Task Activation Diagnosis Effect</measure>
    <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
    <description>Activation beta values (N-Back vs. 0-Back) were extracted within the Main Effect of Diagnosis cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps in the Placebo condition. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>N-Back Task Activation Drug Effect</measure>
    <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
    <description>Activation beta values (N-Back vs. 0-Back) extracted within the Main Effect of Drug cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps across both groups. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>N-Back Task Activation in DLPFC in Patients With Schizophrenia</measure>
    <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
    <description>Activation Beta values (N-Back vs. 0-Back) extracted within the Effect of Drug cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps in patients with schizophrenia. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>N-Back Task Activation in Healthy Volunteers</measure>
    <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
    <description>Activation Beta values (N-Back vs. 0-Back) extracted within the Effect of Drug cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps in Healthy Volunteers. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>N-Back Task Activation Genotype Effect in Healthy Volunteers</measure>
    <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
    <description>Activation beta values (N-Back vs. 0-Back) extracted within the Effect of Genotype cluster around the peak (p &lt; 0.05 uncorrected) in right and left DLPFC from the contrast maps in Healthy Volunteers. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>N-Back Task Activation by Genotype in Patients With Schizophrenia</measure>
    <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
    <description>Activation beta values (N-Back vs. 0-Back) extracted from DLPFC from the contrast maps in Patients with schizophrenia. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale</measure>
    <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
    <description>Rating Scales PANSS. The Positive Scale ranges for 7 to 49 with a higher score indicating greater severity of symptoms. The Negative Scale ranges for 7 to 49 with a higher score indicating greater severity of symptoms. The General Scale ranges from 16 to 112, the higher score indicating greater severity of symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolcapone Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tolcapone one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: One capsule 3 times a day from Day 1 to Day 7</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone</intervention_name>
    <description>Tolcapone: One capsule 3 times a day from Day 1 to Day 7</description>
    <arm_group_label>Tolcapone Arm</arm_group_label>
    <other_name>Tasmar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Prior participation under NIH protocol number 95-M-0150, or new normal volunteers
                  or schizophrenic patients that meet criteria for NIH protocol number 95-M-0150
                  (NCT00001486).

               2. No Axis I or Axis II diagnosis in normal volunteers.

               3. Age range: 18-50 years.

        EXCLUSION CRITERIA:

          1. Normal volunteers with an Axis I or Axis II disorder obtained either from prior SCID
             interview in Protocol 95-M-0150 or through a screening interview will be excluded.

          2. Subjects with a history of cardiovascular disease, liver disease and other medical
             illnesses, and untreated or uncontrolled hypertension will be excluded. An
             electrocardiogram, blood pressure, pulse rate and metabolic panel including LFTs will
             be checked on all subjects prior to participation in the study. Individuals with
             persistent tardive dyskinesia or abnormal LFTs, or individuals with significant
             history of alcoholism or liver enzyme elevation will be excluded from the study.

          3. Schizophrenic patients taking clozapine, a COMT inhibitor, any illicit drugs of abuse,
             or MAO inhibitors will be excluded.

          4. Normal control subjects taking any medications other than occasional NSAI will be
             excluded.

          5. Pregnant women. Women of childbearing potential will undergo a urine pregnancy test
             the day the study initiates and screened by history for the possibility of pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose A Apud, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2002-M-0239.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Aksoy S, Klener J, Weinshilboum RM. Catechol O-methyltransferase pharmacogenetics: photoaffinity labelling and western blot analysis of human liver samples. Pharmacogenetics. 1993 Apr;3(2):116-22.</citation>
    <PMID>8518836</PMID>
  </reference>
  <reference>
    <citation>Andreasen NC, Arndt S, Cizadlo T, O'Leary DS, Watkins GL, Ponto LL, Hichwa RD. Sample size and statistical power in [15O]H2O studies of human cognition. J Cereb Blood Flow Metab. 1996 Sep;16(5):804-16.</citation>
    <PMID>8784225</PMID>
  </reference>
  <reference>
    <citation>Arnsten AF. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol. 1997;11(2):151-62. Review.</citation>
    <PMID>9208378</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>August 16, 2002</study_first_submitted>
  <study_first_submitted_qc>August 16, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2002</study_first_posted>
  <results_first_submitted>March 23, 2018</results_first_submitted>
  <results_first_submitted_qc>June 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2018</results_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Catecholamines</keyword>
  <keyword>Dopamine</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>fMRI</keyword>
  <keyword>PFC</keyword>
  <keyword>Vitamin B2</keyword>
  <keyword>Riboflavin</keyword>
  <keyword>Tolcapone</keyword>
  <keyword>Placebo</keyword>
  <keyword>Normal Volunteers</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolcapone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share data</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with schizophrenia were recruited through families, physicians and community organizations. Healthy volunteers were recruited through the NIH Normal Volunteers Office. Subjects first participated in Protocol # 95-M-0150 to obtain genotype data. If eligible after the study, they were invited to participate in the Tolcapone protocol.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo First Then Tolcapone</title>
          <description>Placebo one week first:
Tolcapone 200 mg second:</description>
        </group>
        <group group_id="P2">
          <title>Tolcapone First, Then Placebo</title>
          <description>Tolcapone one week:
Placebo one week second:</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (One Week)- HV's</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not follow directions</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Used illegal drugs</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal MRI</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Drank while on protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (One Week) HV's</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Intervention (One Week) Patients</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not follow directions</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Used illegal drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (One Week) Patients</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>These numbers represent the total number of subjects (HV's+patients) plus HV's and patients separately that completed the first and second arm of the protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Healthy Volunteers</title>
          <description>Tolcapone 200 mg 1 week:Wash Out 1 week:Placebo 1 week: (or vice versa)</description>
        </group>
        <group group_id="B2">
          <title>Patients</title>
          <description>Tolcapone 200 mg 1 week:Wash Out 1 week:Placebo 1 week: (or vice versa)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="130"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="189"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="9.1"/>
                    <measurement group_id="B2" value="26.9" spread="6.8"/>
                    <measurement group_id="B3" value="32.1" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>N-Back Task Performance</title>
        <description>Working Memory was measured in HVs and patients with schizophrenia after a 7-day treatment with Tolcapone or placebo in a double-blind, cross-over fashion. The working memory was quantified by taking the number of trials entered correctly divided by the total number of trials multiplied by 100. Values range from 0 to 100. Zero indicates the poorest performance while 100 indicates perfect performance.</description>
        <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
        <population>147 HV’s recruited, 8 left after signing consents, 8 excluded for other reasons, 57 excluded for excessive motion, inferior quality or not completion. 63 patients recruited, 4 removed for different reasons, 26 excluded from image analyses for not completing the second phase of the study, excessive motion or bad image quality.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteer on Placebo</title>
            <description>Placebo Days 1-7, Healthy voluntee</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteer Tolcapone</title>
            <description>Day 1: Tolcapone 100 mg tid, Days 2-7: Tolcapone 200 mg tid</description>
          </group>
          <group group_id="O3">
            <title>Patient on Placebo</title>
            <description>Placebo Days 1-7, Patient</description>
          </group>
          <group group_id="O4">
            <title>Patients on Tolcapone</title>
            <description>Day 1: Tolcapone 100 mg tid, Days 2-7: Tolcapone 200 mg tid</description>
          </group>
        </group_list>
        <measure>
          <title>N-Back Task Performance</title>
          <description>Working Memory was measured in HVs and patients with schizophrenia after a 7-day treatment with Tolcapone or placebo in a double-blind, cross-over fashion. The working memory was quantified by taking the number of trials entered correctly divided by the total number of trials multiplied by 100. Values range from 0 to 100. Zero indicates the poorest performance while 100 indicates perfect performance.</description>
          <population>147 HV’s recruited, 8 left after signing consents, 8 excluded for other reasons, 57 excluded for excessive motion, inferior quality or not completion. 63 patients recruited, 4 removed for different reasons, 26 excluded from image analyses for not completing the second phase of the study, excessive motion or bad image quality.</population>
          <units>% of Correct Trials</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.10" spread="1.13"/>
                    <measurement group_id="O2" value="85.50" spread="1.10"/>
                    <measurement group_id="O3" value="76.21" spread="2.31"/>
                    <measurement group_id="O4" value="80.94" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Diagnosis effect on placebo</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <p_value_desc>Drug Effect on Patients</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>N-Back Task Activation Diagnosis Effect</title>
        <description>Activation beta values (N-Back vs. 0-Back) were extracted within the Main Effect of Diagnosis cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps in the Placebo condition. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
        <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
        <population>74 Healthy Volunteers and 33 Patients with Schizophrenia</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteer on Placebo</title>
            <description>Placebo Days 1-7, Healthy Voluntreers</description>
          </group>
          <group group_id="O2">
            <title>Patient on Placebo</title>
            <description>Placebo Days 1-7, Patients</description>
          </group>
        </group_list>
        <measure>
          <title>N-Back Task Activation Diagnosis Effect</title>
          <description>Activation beta values (N-Back vs. 0-Back) were extracted within the Main Effect of Diagnosis cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps in the Placebo condition. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
          <population>74 Healthy Volunteers and 33 Patients with Schizophrenia</population>
          <units>beta value</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.02"/>
                    <measurement group_id="O2" value="0.20" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.02"/>
                    <measurement group_id="O2" value="0.23" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Diagnosis Effect on Placebo in right DLPFC</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>Diagnosis Effect of Placebo in left DLPFC</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>N-Back Task Activation Drug Effect</title>
        <description>Activation beta values (N-Back vs. 0-Back) extracted within the Main Effect of Drug cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps across both groups. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
        <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
        <population>74 Healthy Volunteers and 33 Patients with Schizophrenia</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteers on Placebo</title>
            <description>Placebo Days 1-7, Healthy Volunteers</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers on Tolcapone</title>
            <description>Tolcapone 100 mg TID on Day 1, 200 mg TID Days 2-7.</description>
          </group>
          <group group_id="O3">
            <title>Patients on Placebo</title>
            <description>Placebo Days 1-7, Patients</description>
          </group>
          <group group_id="O4">
            <title>Patients on Tolcapone</title>
            <description>Tolcapone 100 mg TID on Day 1, 200 mg TID Days 2-7</description>
          </group>
        </group_list>
        <measure>
          <title>N-Back Task Activation Drug Effect</title>
          <description>Activation beta values (N-Back vs. 0-Back) extracted within the Main Effect of Drug cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps across both groups. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
          <population>74 Healthy Volunteers and 33 Patients with Schizophrenia</population>
          <units>beta value</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.03"/>
                    <measurement group_id="O2" value="0.11" spread="0.02"/>
                    <measurement group_id="O3" value="0.12" spread="0.04"/>
                    <measurement group_id="O4" value="0.07" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.04"/>
                    <measurement group_id="O2" value="0.25" spread="0.04"/>
                    <measurement group_id="O3" value="0.23" spread="0.05"/>
                    <measurement group_id="O4" value="0.09" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Drug Effect across both groups in left DLPFC</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <p_value_desc>Drug Effect across both groups in right DLPFC</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>N-Back Task Activation in DLPFC in Patients With Schizophrenia</title>
        <description>Activation Beta values (N-Back vs. 0-Back) extracted within the Effect of Drug cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps in patients with schizophrenia. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
        <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
        <population>33 Patients with Schizophrenia</population>
        <group_list>
          <group group_id="O1">
            <title>Patients on Placebo</title>
            <description>Placebo Days 1-7, Patients</description>
          </group>
          <group group_id="O2">
            <title>Patients on Tolcapone</title>
            <description>Day 1 Tolcapone 100 mg tid, days 2-7 Tolcapone 200 mg tid, Patients</description>
          </group>
        </group_list>
        <measure>
          <title>N-Back Task Activation in DLPFC in Patients With Schizophrenia</title>
          <description>Activation Beta values (N-Back vs. 0-Back) extracted within the Effect of Drug cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps in patients with schizophrenia. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
          <population>33 Patients with Schizophrenia</population>
          <units>beta value</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.02"/>
                    <measurement group_id="O2" value="0.24" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.02"/>
                    <measurement group_id="O2" value="0.23" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>The Effect of Drug on Patients with Schizophrenia in right DLPFC</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <p_value_desc>Effect of Drug on Patients with Schizophrenia in left DLPFC</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>N-Back Task Activation in Healthy Volunteers</title>
        <description>Activation Beta values (N-Back vs. 0-Back) extracted within the Effect of Drug cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps in Healthy Volunteers. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
        <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
        <population>74 Healthy Volunteers</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteer on Placebo</title>
            <description>Placebo Days 1-7, Healthy Volunteer</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteer on Tolcapone</title>
            <description>Day 1 Tolcapone 100 mg tid, days 2-7 Tolcapone 200 mg tid</description>
          </group>
        </group_list>
        <measure>
          <title>N-Back Task Activation in Healthy Volunteers</title>
          <description>Activation Beta values (N-Back vs. 0-Back) extracted within the Effect of Drug cluster around the peak (p &lt; 0.05 uncorrected) from the contrast maps in Healthy Volunteers. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
          <population>74 Healthy Volunteers</population>
          <units>beta value</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.03"/>
                    <measurement group_id="O2" value="0.11" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.03"/>
                    <measurement group_id="O2" value="0.36" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>Drug Effect on Healthy Volunteers in left DLPFC</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <p_value_desc>Drug Effect on Healthy Volunteers in right DLPFC</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>N-Back Task Activation Genotype Effect in Healthy Volunteers</title>
        <description>Activation beta values (N-Back vs. 0-Back) extracted within the Effect of Genotype cluster around the peak (p &lt; 0.05 uncorrected) in right and left DLPFC from the contrast maps in Healthy Volunteers. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
        <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteer COMT Val/Val Genotype on Placebo</title>
            <description>Placebo Days 1-7, Healthy Volunteer COMT Val/Val Genotype</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteer COMT Val/Met Genotype on Placebo</title>
            <description>Placebo Days 1-7, Healthy Volunteer COMT Val/Met Genotype</description>
          </group>
          <group group_id="O3">
            <title>Healthy Volunteers COMT Met/Met Genotype on Placebo</title>
            <description>Placebo Days 1-7, Healthy Volunteers COMT Met/Met Genotype</description>
          </group>
          <group group_id="O4">
            <title>Healthy Volunteer COMT Val/Val Genotype on Tolcapone</title>
            <description>Day 1: Tolcapone 100 mg tid, Days 2-7: Tolcapone 200 mg tid Healthy Volunteer COMT Val/Val Genotype</description>
          </group>
          <group group_id="O5">
            <title>Healthy Volunteer COMT Val/Met Genotype on Tolcapone</title>
            <description>Day 1: Tolcapone 100 mg tid, Days 2-7: Tolcapone 200 mg tid Healthy Volunteer COMT Val/Met Genotype</description>
          </group>
          <group group_id="O6">
            <title>Healthy Volunteer COMT Met/Met Genotype on Tolcapone</title>
            <description>Day 1: Tolcapone 100 mg tid, Days 2-7: Tolcapone 200 mg tid Healthy Volunteer COMT Met/Met Genotype</description>
          </group>
        </group_list>
        <measure>
          <title>N-Back Task Activation Genotype Effect in Healthy Volunteers</title>
          <description>Activation beta values (N-Back vs. 0-Back) extracted within the Effect of Genotype cluster around the peak (p &lt; 0.05 uncorrected) in right and left DLPFC from the contrast maps in Healthy Volunteers. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
          <units>beta value</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.03"/>
                    <measurement group_id="O2" value="0.23" spread="0.03"/>
                    <measurement group_id="O3" value="0.14" spread="0.04"/>
                    <measurement group_id="O4" value="0.22" spread="0.03"/>
                    <measurement group_id="O5" value="0.25" spread="0.03"/>
                    <measurement group_id="O6" value="0.15" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.03"/>
                    <measurement group_id="O2" value="0.19" spread="0.03"/>
                    <measurement group_id="O3" value="0.10" spread="0.03"/>
                    <measurement group_id="O4" value="0.14" spread="0.03"/>
                    <measurement group_id="O5" value="0.18" spread="0.03"/>
                    <measurement group_id="O6" value="0.09" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Main Effect of Genotype across both Placebo and Tolcapone in right DLPFC</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.167</p_value>
            <method>ANOVA</method>
            <method_desc>Main Effect of Genotype across both Placebo and Tolcapone in left DLPFC</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>N-Back Task Activation by Genotype in Patients With Schizophrenia</title>
        <description>Activation beta values (N-Back vs. 0-Back) extracted from DLPFC from the contrast maps in Patients with schizophrenia. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
        <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
        <population>33 patients with schizophrenia</population>
        <group_list>
          <group group_id="O1">
            <title>Patients COMT Val/Val Genotype on Placebo</title>
            <description>Placebo Days 1-7, Patients COMT Val/Val Genotype</description>
          </group>
          <group group_id="O2">
            <title>Patients COMT Val/Met Genotype on Placebo</title>
            <description>Placebo Days 1-7, Patients COMT Val/Met Genotype</description>
          </group>
          <group group_id="O3">
            <title>Patients COMT Met/Met Genotype on Placebo</title>
            <description>Placebo Days 1-7, Patients COMT Met/Met Genotype</description>
          </group>
          <group group_id="O4">
            <title>Patients COMT Val/Val Genotype on Tolcapone</title>
            <description>Day 1: Tolcapone 100 mg tid, Days 2-7: Tolcapone 200 mg tid</description>
          </group>
          <group group_id="O5">
            <title>Patients COMT Val/Met Genotype on Tolcapone</title>
            <description>Day 1: Tolcapone 100 mg tid, Days 2-7: Tolcapone 200 mg tid</description>
          </group>
          <group group_id="O6">
            <title>Patients COMT Met/Met Genotype on Tolcapone</title>
            <description>Day 1: Tolcapone 100 mg tid, Days 2-7: Tolcapone 200 mg tid</description>
          </group>
        </group_list>
        <measure>
          <title>N-Back Task Activation by Genotype in Patients With Schizophrenia</title>
          <description>Activation beta values (N-Back vs. 0-Back) extracted from DLPFC from the contrast maps in Patients with schizophrenia. Lower beta values reflect more efficient processing in the DLPFC when performing working memory tasks.</description>
          <population>33 patients with schizophrenia</population>
          <units>beta value</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>right DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.05"/>
                    <measurement group_id="O2" value="0.23" spread="0.03"/>
                    <measurement group_id="O3" value="0.24" spread="0.04"/>
                    <measurement group_id="O4" value="0.25" spread="0.05"/>
                    <measurement group_id="O5" value="0.20" spread="0.03"/>
                    <measurement group_id="O6" value="0.22" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>left DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.04"/>
                    <measurement group_id="O2" value="0.24" spread="0.03"/>
                    <measurement group_id="O3" value="0.21" spread="0.04"/>
                    <measurement group_id="O4" value="0.18" spread="0.05"/>
                    <measurement group_id="O5" value="0.26" spread="0.04"/>
                    <measurement group_id="O6" value="0.17" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.189</p_value>
            <p_value_desc>Drug by Genotype Effect in left DLPFC</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <p_value_desc>Drug Effect on Val/Val Genotype in left DLPFC</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.718</p_value>
            <p_value_desc>Drug Effect on Val/Met Genotype in left DLPFC</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.469</p_value>
            <p_value_desc>Drug Effect of Met/Met Genotype in left DLPFC</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Syndrome Scale</title>
        <description>Rating Scales PANSS. The Positive Scale ranges for 7 to 49 with a higher score indicating greater severity of symptoms. The Negative Scale ranges for 7 to 49 with a higher score indicating greater severity of symptoms. The General Scale ranges from 16 to 112, the higher score indicating greater severity of symptoms.</description>
        <time_frame>At end of treatment period (at 7th day for first intervention and at 21st day for second intervention)</time_frame>
        <population>There were 74 Healthy Volunteers and 33 Patients with Schizophrenia</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteer on Placebo</title>
            <description>Placebo Days 1-7, Healthy volunteer</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteer Tolcapone</title>
            <description>Day 1: Tolcapone 100 mg tid, Days 2-7: Tolcapone 200 mg tid</description>
          </group>
          <group group_id="O3">
            <title>Patient on Placebo</title>
            <description>Placebo Days 1-7, Patient</description>
          </group>
          <group group_id="O4">
            <title>Patients on Tolcapone</title>
            <description>Day 1: Tolcapone 100 mg tid, Days 2-7: Tolcapone 200 mg tid</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Syndrome Scale</title>
          <description>Rating Scales PANSS. The Positive Scale ranges for 7 to 49 with a higher score indicating greater severity of symptoms. The Negative Scale ranges for 7 to 49 with a higher score indicating greater severity of symptoms. The General Scale ranges from 16 to 112, the higher score indicating greater severity of symptoms.</description>
          <population>There were 74 Healthy Volunteers and 33 Patients with Schizophrenia</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.01" spread="0.01"/>
                    <measurement group_id="O2" value="7.02" spread="0.03"/>
                    <measurement group_id="O3" value="12.15" spread="0.51"/>
                    <measurement group_id="O4" value="12" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.36" spread="0.14"/>
                    <measurement group_id="O2" value="7.27" spread="0.13"/>
                    <measurement group_id="O3" value="16.51" spread="1.00"/>
                    <measurement group_id="O4" value="15.88" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Psychopathology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.36" spread="0.10"/>
                    <measurement group_id="O2" value="16.33" spread="0.09"/>
                    <measurement group_id="O3" value="27.12" spread="0.78"/>
                    <measurement group_id="O4" value="26.24" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7</p_value>
            <p_value_desc>Drug Effect on Positive Syndrome for Patients</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4</p_value>
            <p_value_desc>Drug Effect on Negative Syndrome for Patients</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>Drug Effect on General Pathology for Patients</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to Day 21</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthy Volunteers on Placebo</title>
          <description>Placebo Days 1-7, Healthy Volunteers</description>
        </group>
        <group group_id="E2">
          <title>Healthy Volunteers on Tolcapone</title>
          <description>Tolcapone 100 mg TID on Day 1, 200 mg TID Days 2-7.</description>
        </group>
        <group group_id="E3">
          <title>Patients on Placebo</title>
          <description>Placebo Days 1-7, Patients</description>
        </group>
        <group group_id="E4">
          <title>Patients on Tolcapone</title>
          <description>Tolcapone 100 mg TID on Day 1, 200 mg TID Days 2-7</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea was present in two patients in both arms of the protocol.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Diarrhea was present in one patient in both arms of the protocol.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite Problems</sub_title>
                <description>Appetite problem was present in two patients in both arms of the protocol.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stiffness</sub_title>
                <description>Stiffness present in four patients in both arms of the protocol.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep Problems</sub_title>
                <description>Sleep problems was present in three patients in both arms of the protocol.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Halluciantions</sub_title>
                <description>Hallucination was present in nine patients in both arms of the protocol. On patient reported hallucinations only on the placebo arm of the protocol.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There was an early termination due to a request from the NIMH leadership to assess if was justifiable to continue when considering costs of this research and needs to assess resources to develop new protocols for the Branch</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jose A. Apud</name_or_title>
      <organization>Office of the Clinical Director-NIMH-NIH-HHS</organization>
      <phone>3015946561</phone>
      <email>apudj@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

